Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04759781 · ClinicalTrials.gov registry record
MElanoma Research Lymph Node Prediction Implementation National_001
A clinical trial of Melanoma, sponsored by SkylineDx.
- Active
- Registry status
- 1,820
- Enrollment target
- 9
- Study locations
NCT04759781: Active study of Melanoma, sponsored by SkylineDx.
NCT04759781 is a study of Melanoma that is active but no longer recruiting, run by SkylineDx. The registered enrollment target is 1,820 participants, above the 700-participant average among 266 other Melanoma trials with a reported enrollment target (160% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04759781, a study of Melanoma, is active but no longer recruiting, sponsored by SkylineDx.
- ACTIVE NOT RECRUITING
- Registry status
- 1,820 participants
- Enrollment target
- 9
- Study locations
Study Summary
MERLIN\_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Primary Outcome
The predictive capability of the Merlin Assay to identify newly diagnosed primary cutaneous melanoma patients who have a low risk of presenting with a positive sentinel lymph node.
Conditions Studied
Study Locations (9)
Kentucky
- University of Kentucky - Lexington
- University of Louisville - Louisville
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University School of Medicine - Atlanta
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University - Durham
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,820 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2029-06 |
What the registry record for NCT04759781 still lists
NCT04759781 is an observational study that tracks outcomes without assigning an intervention. Its 1,820 participants enrollment target places it among the larger protocols in the corpus, above the 700-participant average among 266 other Melanoma trials with a reported enrollment target (160% higher).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT04759781 lists 9 locations in 8 states (Kentucky, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT04759781 about?
NCT04759781 is a clinical study titled "MElanoma Research Lymph Node Prediction Implementation National_001". MERLIN\_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
What is the current status of trial NCT04759781?
This trial is currently active not recruiting. The enrollment target is 1,820 participants. The study started on 2021-08-25. Estimated completion is 2029-06.
What conditions does trial NCT04759781 study?
This clinical trial studies the following conditions: Melanoma.
Who is sponsoring clinical trial NCT04759781?
This trial is sponsored by SkylineDx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04759781 being conducted?
This trial has 9 study locations across Florida, Georgia, Kentucky, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04759781's enrollment target sits among peer trials
1,820 11th of 266 higher than 256 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI